文献速递慢性肾脏病

周围神经病变是3-4期慢性肾脏病患者活动受限与疾病负担的重要贡献因素

Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究为前瞻性观察研究,纳入109例eGFR 15-60 mL/min/1.73 m2的3-4期慢性肾脏病患者,采用总神经病变评分评估周围神经病变,并分析其与步行速度及生活质量的关系。结果显示40%患者有轻度神经病变、37%有中重度神经病变;神经病变严重程度是步行速度降低的主要预测因素(R2=-0.41,P<0.001),且与SF-36多个维度低评分相关。

要点

  • 3-4期CKD患者中周围神经病变高发,40%轻度、37%中重度
  • 神经病变严重程度是步行速度降低的主要预测因素,独立于糖尿病状态
  • 神经病变与SF-36多个维度低评分显著相关,包括躯体功能(r=-0.570,P<0.001)

核心结论

  • 中重度周围神经病变在3-4期CKD中常见,与步行速度降低独立于糖尿病状态相关,并与患者报告的生活质量相关。
  • 神经病变是CKD进展中躯体功能下降的重要贡献因素,无论是否合并糖尿病。

研究设计与样本

  • 前瞻性观察研究,连续纳入109例eGFR 15-60 mL/min/1.73 m2的3-4期CKD患者。
  • 采用总神经病变评分评估周围神经病变的存在与严重程度,评估常速与最大步行速度,采用SF-36问卷评估生活质量。

主要发现

  • 40%患者为轻度神经病变,37%为中重度神经病变。
  • 神经病变严重程度是步行速度降低的主要预测因素(R2=-0.41,P<0.001),多变量分析调整糖尿病后仍显著。
  • 神经病变与SF-36多个维度低评分显著相关,包括躯体功能(r=-0.570,P<0.001)。
  • 亚组分析显示合并与不合并糖尿病患者中神经病变均高发,与步行速度的关系在亚组分析中仍明显;但糖尿病患者神经病变更严重、步行速度更慢、生活质量评分更低。

临床怎么用

  • 在3-4期CKD患者中应关注周围神经病变的筛查与评估,因其与步行速度下降和生活质量受损相关。
  • 针对周围神经病变的诊断与管理可能有助于改善CKD患者的躯体功能与生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Impaired physical function drives adverse outcomes in chronic kidney disease (CKD). Peripheral neuropathy is highly prevalent in CKD, though its contribution to physical function in CKD patients is unknown. This study examined the relationships between peripheral neuropathy, walking speed and quality of life (QoL) in stages 3 and 4 CKD. METHODS: This was a prospective observational study investigating neuropathy in CKD patients with an estimated glomerular filtration rate (eGFR) 15-60 mL/min/1.73 m2. A total of 109 patients were consecutively recruited. The presence and severity of peripheral neuropathy was determined using the total neuropathy score. Walking speed was assessed at both usual and maximal speed, and QoL was assessed using the Short- Form 36 (SF-36) questionnaire. RESULTS: Peripheral neuropathy was highly prevalent: 40% demonstrated mild neuropathy and 37% had moderate-severe neuropathy. Increasing neuropathy severity was the primary predictor of reduced walking speed (R2 = -0.41, P < 0.001) and remained so after multivariable analysis adjustment for diabetes. This association was evident for both usual and maximal walking speeds. Neuropathy correlated significantly with low scores on multiple domains of SF-36 including physical function (r = -0.570, P < 0.001). Subanalysis according to diabetic status revealed a high prevalence of neuropathy both with and without diabetes; relationships to walking speed remained evident in subgroup analysis. However, those with diabetes demonstrated greater severity of neuropathy, slower walking speed and lower scores in QoL. CONCLUSIONS: Moderate to severe peripheral neuropathy was common in stages 3 and 4 CKD, associated with reduced walking speed independent of diabetes status and was correlated with patient-reported QoL. This suggests that neuropathy is an important contributor to declining physical function in CKD irrespective of diabetes status. Targeted diagnosis and management of peripheral neuropathy during CKD progression may improve functional outcomes and QoL.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Arnold R, Pianta TJ, Issar T, et al. Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease. Nephrol Dial Transplant. 2022. PMID: 33576810. doi:10.1093/ndt/gfab043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。